Suppr超能文献

神经功能完好的胸腰椎爆裂骨折患者手术与非手术治疗的成本效益分析

Surgical versus nonsurgical treatment of thoracolumbar burst fractures in neurologically intact patients: a cost-utility analysis.

作者信息

Dandurand Charlotte, Öner Cumhur F, Schnake Klaus John, Bransford Richard J, Schroeder Greg D, Dea Nicolas, Phillips Mark R, Joeris Alexander, El-Sharkawi Mohammad, Rajasekaran Shanmuganathan, Benneker Lorin M, Tee Jin W, Popescu Eugen Cezar, Paquet Jérôme, France John C, Vaccaro Alexander R, Dvorak Marcel F

机构信息

Department of Orthopaedics, University of British Columbia, Vancouver, British Columbia, Canada.

University Medical Center, Utrecht, The Netherlands.

出版信息

Spine J. 2025 Jul;25(7):1494-1507. doi: 10.1016/j.spinee.2025.01.030. Epub 2025 Jan 31.

Abstract

BACKGROUND CONTEXT

Many efforts have been made to determine what is the best treatment strategy for neurologically intact patients with TL burst fractures: surgery or nonoperative management. Studies comparing clinical outcomes have produced mixed and inconclusive results creating lack of consensus in the expert community.

PURPOSE

Therefore, it is necessary to explore other important components of healthcare such as economics to settle this controversial debate. The goal of the current study was to perform a cost-utility analysis comparing surgical treatment to nonoperative treatment for neurologically intact TL burst fractures (AOSpine classification types A3 and A4) from a societal perspective in a multicenter and international setting.

STUDY DESIGN/SETTING: We performed a cost-utility analysis from a societal perspective comparing the cost-utility of surgical treatment versus nonsurgical treatment of thoracolumbar (TL) burst fractures in neurologically intact patients.

PATIENT SAMPLE

Patient demographics and all clinical and outcome data were taken from an observational, prospective multicenter cohort study comparing surgical versus nonsurgical treatment of TL burst fractures in neurological intact patients.

OUTCOME MEASURES

The ICER was calculated comparing surgical versus nonsurgical treatment for the full analysis population with a 1-year time horizon, two-year time horizon as well as the working-life time horizon. Costs were taken from the clinical study, patient diaries with productivity loss documented, current scientific literature in addition to national and international healthcare costing guidelines and databases.

METHODS

The mean difference in cost between the two treatment groups were calculated, firstly by applying the central limit theorem, and secondly by using bootstrapping. To calculate the average cost per patient in each treatment group, the Kaplan-Meier Sample Average (KMSA) estimator was used in order to take account of the censored patients. To evaluate the derived models and to explore uncertainty, sensitivity analysis was used.

RESULTS

Eleven sites from different regions (North America, Europe, Middle east, and Asia) completed the recruitment and follow-up for 213 patients. One hundred and thirty patients were treated surgically (61.0%) and eighty-three patients (39.0%) were treated nonsurgically. At 1-year, the ICER for surgical treatment was $191,648.00 USD per QALY. Compared to a willingness to pay threshold of $100,000, surgical treatment was not cost-effective within the 1-year timeframe. At 2-years, the nonsurgical group had visited the surgeon or general practitioner more often (0.31 vs 0.25). The nonsurgical group had visited physiotherapist and other allied health more often (3.68 vs 1.68). The utilization of NSAIDs and opioids remained higher in the nonsurgical group (2.66 vs 2.39) (1.52 vs 0.75). The average workdays lost remained higher in the nonsurgical group (143.12 vs 114.78). The caregiver days taken off work remained higher in the nonsurgical group (29.86 vs 2.39). At 2 years, surgical treatment showed to be a dominant strategy with a $28,978.50 savings per QALY. At lifetime horizon, surgical treatment remained the cost-effective strategy at $25,530.18 savings per QALY.

CONCLUSION

Our cost-utility analysis showed surgical management to be cost-effective at 2 years compared to nonoperative management in neurologically intact TL burst fractures from a societal perspective. This finding was maintained through the working-lifetime horizon. Surgical treatment became cost-effective largely due to the greater productivity loss of patients and caregivers within the nonsurgical group. This investigation highlights the viability for surgical management of TL burst fractures to provide societal benefit especially when productivity is valued.

摘要

背景

为确定神经功能完好的胸腰段爆裂骨折患者的最佳治疗策略是手术还是非手术治疗,人们已做出诸多努力。比较临床结果的研究产生了复杂且无定论的结果,在专家群体中未达成共识。

目的

因此,有必要探索医疗保健的其他重要组成部分,如经济学,以解决这一有争议的争论。本研究的目的是从社会角度,在多中心和国际背景下,对神经功能完好的胸腰段爆裂骨折(AOSpine分类A3和A4型)的手术治疗与非手术治疗进行成本效用分析。

研究设计/背景:我们从社会角度进行了成本效用分析,比较神经功能完好的患者胸腰段爆裂骨折手术治疗与非手术治疗的成本效用。

患者样本

患者人口统计学资料以及所有临床和结局数据均取自一项观察性、前瞻性多中心队列研究,该研究比较了神经功能完好的患者胸腰段爆裂骨折的手术治疗与非手术治疗。

结局指标

计算增量成本效果比(ICER),比较全分析人群手术治疗与非手术治疗在1年时间范围、2年时间范围以及工作寿命时间范围的情况。成本取自临床研究、记录有生产力损失的患者日记、当前科学文献以及国家和国际医疗保健成本核算指南与数据库。

方法

首先应用中心极限定理,其次使用自抽样法计算两个治疗组之间的平均成本差异。为计算每个治疗组中每位患者的平均成本,使用Kaplan-Meier样本均值(KMSA)估计器以考虑截尾患者。为评估推导模型并探索不确定性,使用了敏感性分析。

结果

来自不同地区(北美、欧洲、中东和亚洲)的11个地点完成了213例患者的招募和随访。130例患者接受手术治疗(61.0%),83例患者(39.0%)接受非手术治疗。在1年时,手术治疗的ICER为每质量调整生命年191,648.00美元。与100,000美元的支付意愿阈值相比,手术治疗在1年时间范围内不具有成本效益。在2年时,非手术组更频繁地拜访外科医生或全科医生(0.31次对0.25次)。非手术组更频繁地拜访物理治疗师和其他专职医疗人员(3.68次对1.68次)。非手术组非甾体抗炎药和阿片类药物的使用仍然更高(2.66次对2.39次)(1.52次对0.75次)。非手术组平均损失的工作日仍然更高(143.12天对114.78天)。非手术组护理人员请假天数仍然更高(29.86天对2.39天)。在2年时,手术治疗显示为优势策略,每质量调整生命年节省28,978.50美元。在终身时间范围,手术治疗仍然是成本效益策略,每质量调整生命年节省25,530.18美元。

结论

我们的成本效用分析表明,从社会角度来看,在神经功能完好的胸腰段爆裂骨折患者中,与非手术治疗相比,手术治疗在2年时具有成本效益。这一发现贯穿工作寿命时间范围。手术治疗变得具有成本效益主要是由于非手术组患者和护理人员更大的生产力损失。这项研究突出了胸腰段爆裂骨折手术治疗提供社会效益的可行性,尤其是在重视生产力的情况下。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验